Editorial · 31 Mar 2025
EditorialPublished 1 May 2020
The Atherosclerosis and Lipid Lowering- is there a Need for New Agents
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Statins has substantially reduced CVD events around the world and is recommended as firstlLne therapy for CVD management. However, a need for other lipid-lowering agents, because some patients do not tolerate statins due to adverse events, or cannot reach LDL-C level desired because of high levels of LDL-C, or patients with very high risk cardiovascular events need more intensive reduction therapy [7-9]. Can we pay the benefits of these new agents when statins are eوٴectLve and inexpensive? Zhang et al. reported a meta-analysis study to evaluate the safety and eٹcac\ of anti-PCSK9 antibodies in randomized, controlled trials (RCTs). 7went\five RCTs encompassing 12,200 patients were included. Нe study showing largely no sLJnLficant dLوٴerence between anti-PCSK9 antibodies and placebo (or ezetimibe), except that alirocumab was associated with reduced rates of death (relative risk (RR): 0.43, 95 % CI: 0.19 to 0.96, P=0.04) and an increased rate of injection-site reactions (RR: 1.48, 95 % CI: 1.05 to 2.09, P=0.02)
Keywords
Subjects
CardiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Atherosclerosis: Open Access.
Editorial · 31 Mar 2025
Understanding Dyslipidemia: Causes, Risks, and Management
Editorial · 31 Mar 2025
Diabetes and Atherosclerosis: A Dangerous Partnership in Cardiovascular Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalAtherosclerosis: Open Access
- SubjectCardiology
- BylineArticles whose byline prints “Leonardo Roever”